FDA grants priority review to Merck’s supplemental biologics license application for KEYTRUDA® (pembrolizumab) as adjuvant therapy in certain patients with renal cell carcinoma (RCC) following surgery. News release. Merck. August 10, 2021. Accessed August 10, 2021. https://bit.ly/3fLSKFG